Corcept Therapeutics
Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CORT
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.
CORT Key Statistics
Stock Snapshot
Corcept Therapeutics(CORT) stock is priced at $40.31, giving the company a market capitalization of 4.29B. It carries a P/E multiple of 46.59.
During the trading session on 2026-03-31, Corcept Therapeutics(CORT) shares reached a daily high of $40.40 and a low of $38.44. At a current price of $40.31, the stock is +4.9% higher than the low and still -0.2% under the high.
Trading volume for Corcept Therapeutics(CORT) stock has reached 1.51M, versus its average volume of 2.87M.
The stock's 52-week range extends from a low of $28.66 to a high of $117.33.
The stock's 52-week range extends from a low of $28.66 to a high of $117.33.
CORT News
Corcept Therapeutics (CORT) presented late-breaking data from its Momentum trial examining the prevalence of endogenous hypercortisolism in patients with resist...
For investors considering whether Corcept Therapeutics at around US$38.53 is a bargain or a potential risk, this article walks through what the current price mi...
Wolfe Research analyst Kalpit Patel upgraded Corcept Therapeutics (CORT) to Peer Perform from Underperform with no price target after the company received appro...
Analyst ratings
71%
of 7 ratingsMore CORT News
Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $110 from $100 and keeps a Buy rating on the shares. The firm noted the FDA posted on...
Earlier this year, Corcept Therapeutics announced that the FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for adults with previously treated platinum-...
Key Points This is Lyforli, a cancer treatment. It was developed by the company using a unique approach focused on the hormone cortisol. 10 stocks we like be...
The latest update is out from Corcept Therapeutics ( (CORT) ). On March 25, 2026, Corcept Therapeutics announced U.S. FDA approval of Lifyorli (relacorilant) i...
Shares in biopharma company Corcept Therapeutics (CORT) climbed as high as 48% to $48.35 following U.S. approval of Lifyorli for treating certain ovarian-type c...
10:33 EDT FDA approves Corcept Therapeutics (CORT)’ Lifyorli for certain cancers Published first on TheFly – the ultimate source for real-time, market-moving b...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.